DENND2D and cancer: Several experimentally validated targets of miR‐522 in human cancers have been documented, including ABCB5, BLM, MAOB, PHLPP1, DKK1, SFRP2, DENND2D, SOCS5 and PPM1A [20, 23, 24, 25, 26, 29, 30, 31, 45].